Valuation: Ipca Laboratories Limited

Market Cap 443B 4.65B 4.04B 3.76B 3.45B 6.52B 6.62B 44.3B 17.39B 221B 17.45B 17.06B 740B P/E 2027 *
31.8x
P/E 2028 * 26.6x
Enterprise Value 432B 4.52B 3.93B 3.66B 3.36B 6.34B 6.44B 43.12B 16.92B 215B 16.98B 16.61B 720B EV / Sales 2027 *
4.01x
EV / Sales 2028 * 3.5x
Free-Float
54.92%
Yield 2027 *
0.33%
Yield 2028 * 0.36%
1 day-0.81%
1 week-0.88%
1 month+2.99%
3 months+14.10%
6 months+24.17%
Current year+22.69%
1 week 1,724.8
Extreme 1724.8
1,802.5
1 month 1,724.8
Extreme 1724.8
1,941.4
Current year 1,392
Extreme 1392
1,941.4
1 year 1,252.95
Extreme 1252.95
1,941.4
3 years 849.25
Extreme 849.25
1,941.4
5 years 670
Extreme 670
1,941.4
10 years 200
Extreme 200
1,941.4
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2023
Chief Executive Officer 70 01/04/2023
Chief Tech/Sci/R&D Officer 52 16/10/2023
Director TitleAgeSince
Chairman 79 05/07/2012
Director/Board Member 53 11/11/2008
Director/Board Member 70 01/08/1994
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-0.88% - - 4.65B
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
Average -1.27%-1.21%+26.03%+42.41% 379.88B
Weighted average by Cap. -1.00%-2.02%+36.14%+71.90%

Financials

2027 *2028 *
Net sales 108B 1.13B 981M 913M 838M 1.58B 1.61B 10.76B 4.22B 53.61B 4.24B 4.14B 180B 120B 1.26B 1.09B 1.02B 934M 1.76B 1.79B 12B 4.71B 59.78B 4.72B 4.62B 200B
Net income 14B 147M 127M 119M 109M 206M 209M 1.4B 549M 6.97B 551M 539M 23.37B 16.7B 175M 152M 142M 130M 245M 249M 1.67B 655M 8.31B 657M 642M 27.87B
Net Debt -11.82B -124M -108M -100M -92.02M -174M -176M -1.18B -464M -5.89B -465M -455M -19.74B -23.66B -248M -215M -201M -184M -348M -353M -2.36B -928M -11.78B -931M -910M -39.5B
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
17,210
Date Price Change Volume
31/07/26 INR 1,747.15 -0.81% 63,070
30/07/26 INR 1,761.50 -0.72% 3,513
29/07/26 INR 1,774.30 -0.14% 3,128
28/07/26 INR 1,776.70 -0.03% 6,133
27/07/26 INR 1,777.25 +0.83% 8,534
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,747.80INR
Average target price
1,733.50INR
Spread / Average Target
-0.82%

Quarterly revenue - Rate of surprise